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TO THE EDITOR
Transgenic mouse models of melanoma
driven by melanocyte-specific expres-
sion of oncogenes have been devel-
oped to study gene–gene and
gene–environment interactions (Dams-
ky and Bosenberg, 2010). Oncogene
expression can be constitutive or in-
ducible, but is generally insufficient for
melanomagenesis unless tumor-sup-
pressor genes are deleted (Pten, Tp53,
Cdkn2a), or the mice are exposed to
mutagens such as UV light. Critically,
in mice melanoma is largely restricted
to the dermal layers of the skin and the
epidermis is rarely involved, whereas
human cutaneous malignant melanoma
generally develops in the epidermis and
then invades the deeper layers of skin.
This difference presumably occurs
because mouse melanocytes are pre-
dominantly located in the follicles and
dermis and provide pelt pigmentation,
whereas human melanocytes are pre-
dominantly epidermal and provide pro-
tection from UV light.
Melanocyte location in the skin is
controlled by the KIT ligand (KITL).
Human keratinocytes express KITL
throughout life and melanocytes persist
in the epidermis. In postnatal mouse
skin, KITL expression is restricted to
the hair matrix (Yoshida et al., 2001)
and the melanocytes are largely located
in the follicles. However, if mouse
keratinocytes are engineered to express
KITL using the keratin-14 gene pro-
moter (K14-Kitl), a proportion of the
melanocytes remain in the epidermis
throughout life (Kunisada et al., 1998).
Using this approach, melanoma driven
by tyrosinase-expressed Q61KNras
(Tyr-Q61KNras), p19Arf deletion, and
neonatal UV light exposure can be
translocated to the mouse epidermis
(Walker et al., 2011).
The protein kinase BRAF is mutated
in about half of human melanomas
and we developed a V600EBraf-driven
mouse melanoma model using the
tamoxifen-activated Cre-recombinase/
loxP technology (Dhomen et al.,
2009). V600EBraf-driven melanomas are
exclusively dermal (Dhomen et al.,
2009); therefore we tested whether
a membrane-bound version of KITL
under the control of the K14 promoter
could translocate these tumors to the
epidermis. All animal procedures were
approved by the local animal ethics
committee (ICR) in accordance with the
Home Office regulations under the
Animals (Scientific Procedures) Act of
1986 (Workman et al., 2010). When
LSL-V600EBraf::Tyr-CreERT2 (henceforth
V600EBraf) mice were crossed with K14-
Kitl mice, we observed S100-positive
melanocytes in the basal layers of the
interfollicular epidermis (Figure 1a)
and melanin capping of the nuclei
in the keratinocytes (Figure 1b). These
features were absent in V600EBraf
mice (Figures 1a and b). As previously
described (Dhomen et al., 2009),
V600EBraf induced mild hyperpigmenta-
tion of the ears and feet (Figure 1c).
Notably, KITL also induced increased
pigmentation of the feet and ears
and V600EBraf further enhanced this
effect (Figure 1c).
V600EBraf also induced nevi compris-
ing pigmented epithelioid and dendritic
melanocytes in the deep reticular der-
mis and hypodermis of the skin (Figure
1d; see Dhomen et al., 2009). How-
ever, in V600EBraf::K14-Kitl mice,
V600EBraf induced highly cellular nevi
presenting large populations of pig-
ment-laden epithelioid and dendritic
melanocytes that occasionally formed
ill-defined nests (Figure 1d; Supplemen-
tary Figure S1 online). Nevi in V600EB-
raf::K14-Kitl mice were located in the
papillary and reticular dermis and were
separated from the epidermis by a
narrow Grenz zone. They occasionally
reached the hypodermis surrounding
the adnexae, but did not present an
epidermal component (Figure 1d; Sup-
plementary Figure S1 online).
V600EBraf also induced rapidly grow-
ing skin tumors in V600EBraf and V600EB-
raf::K14-Kitl mice (Figure 2a). The
tumors from the two strains of mice
were macroscopically similar, but
developed with a significantly lower
latency in the V600EBraf::K14-Kitl mice
(4.8 compared with 12.5 months; log-
rank test Po0.0001; Figure 2b). V600EB-
raf::K14-Kitl mice also showed greater
tumor penetrance (100% in 7 months
compared with 70% in 24 months;
Figure 2b) and developed a greater
number of tumors (average 3 compared
with 0.78; Figure 2c).
Using PCR, we showed that
LSL-V600EBraf was recombined in
tumors from V600EBraf::K14-Kitl mice
(Figure 2d), and using RT-PCR we
confirmed the expression of the mela-
nocytic markers tyrosinase, silver
(gp100), Mitf-M, Dct (Trp2), Sox10,
Pax3, and Pou3f2 (Brn2; Figure 2e).
S100 expression was confirmed by
immunostaining (Figure 2f). These data
are consistent with a diagnosis of
malignant melanoma. The smaller,
less advanced tumors presented an
intact epidermis and pigmented
melanocytes in the reticular dermis,
suggestive of residual intradermal
nevi (Figure 2g). These lesions were
generally amelanotic, paucicellular,
and composed of spindle/dendriticAbbreviations: EtOH, ethanol; KITL, KIT ligand; mGluR1, metabotropic glutamate receptor-1
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melanocytes occupying the deeper
layers of skin (Figure 2h). The larger
lesions were generally asymmetric,
poorly circumscribed, and within the
superficial dermis (Figure 2i). Promi-
nent ulceration and effacement of the
epidermis were common (Figure 2j),
as was locally destructive invasion
into the subcutaneous layers (Figure 2i
and k). These tumors were also gener-
ally amelanotic, with rare pigmented
melanocytes occupying the superficial
aspects. The deeper aspects were com-
posed of atypical spindle melanocytes
occasionally arranged in storiform pat-
terns (Figure 2l). Mitotic figures were
abundant (Figure 2m). Crucially, as in
V600EBraf mice (Dhomen et al., 2009),
the tumors in V600EBraf::K14-Kitl mice
were exclusively dermal; neither epi-
dermal invasion nor a junctional com-
ponent was observed (Figures 2g, i, j,
and l), and we note that K14-Kitl also
failed to translocate melanoma driven
by the metabotropic glutamate receptor-
1 (mGluR1) to the epidermis (Abdel-
Daim et al., 2010).
We set out to translocate V600EBraf
tumors to the epidermis using K14-Kitl.
We cannot discount the possibility that
rare melanoma cells did colonize the
epidermis, but overall the V600EBraf::
K14-Kitl melanomas appeared to be
exclusively dermal. This may be be-
cause, although melanocytes do occupy
the epidermis of V600EBraf::K14-Kitl
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Figure 1. Skin phenotype comparisons in
V600EBraf and V600EBraf::K14-Kitl mice before
and after tamoxifen treatment. (a) Photomicro-
graphs showing S100 staining in skin sections
from control (EtOH-treated) V600EBraf and
V600EBraf::K14-Kitl mice. The boxed region in the
upper panels is enlarged below the images.
White arrow shows the presence of S100-positive
cells in the epidermis. Upper panel: bar¼150 mm,
lower panel: bar¼ 50mm. (b) Hematoxylin and
eosin (H&E) staining of skin sections from control
V600EBraf and V600EBraf::K14-Kitl mice. The boxed
region in the upper panels is enlarged below the
images. Black arrow indicates keratinocyte with
melanin cap. Upper panel: bar¼ 150mm, lower
panel: bar¼ 50mm. (c) Photographs showing
footpads and ears of V600EBraf and V600EBraf::
K14-Kitl mice approximately 4 months after EtOH
control (Cont.) or tamoxifen (Tam.) treatment.
Dashed lines indicate adjacent panel regions
that were cropped from the same photograph and
processed as a single image. (d) H&E staining
of skin sections and dermal nevi from tamoxifen-
treated V600EBraf and V600EBraf::K14-Kitl mice.
The boxed region in the upper panels is enlarged
below the images. White arrows indicate skin
adnexae (hair follicles and associated sebaceous
glands). Upper panel: bar¼ 0.5 cm, lower
panel: bar¼ 200mm.
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mice, B90% of the melanocytes
remain dermal (Supplementary Figure
S2 online); therefore, the probability of
developing dermal melanoma may
simply be higher. However, we exam-
ined 30 tumors andB50 nevi and found
no evidence of epidermal lesions, sug-
gesting that these are not chance events
and that even when expressing KITL, the
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Figure 2. Melanocyte-specific V600EBraf expression leads to development of skin tumors in V600EBraf and V600EBraf::K14-Kitl mice characteristic of malignant
melanoma. (a) Photographs of V600EBraf and V600EBraf::K14-Kitl mice presenting skin tumors at similar stages of development. (b) Kaplan–Meier curve showing
tumor-free survival in V600EBraf (n¼32), V600EBraf::K14-Kitl mice (n¼ 12), and controls (n¼16, comprising EtOH-treated V600EBraf::K14-Kitl and tamoxifen-
treated K14-Kitl::Tyr-CreERT mice). The difference between the V600EBraf and V600EBraf::K14-Kitl curves is statistically significant (Po0.0001; Mantel–Cox
log-rank test). (c) Scatter plot showing tumor number at point of cull, due to tumor burden or having reached the end of the 24-month experimental period, in
V600EBraf (n¼ 32) and V600EBraf::K14-Kitl mice (n¼ 12). The P-value was calculated using Student’s t-test. (d) PCR-mediated genotyping of tumors (T) or kidney
(K) from three V600EBraf::K14-Kitl mice (no. 453, no. 804, and no. 806). The positions of the wild-type Braf allele (WT-Braf), the unrecombined LSL-V600EBraf
allele (LSL-V600EBraf), and the recombined LSL-V600EBraf allele (Lox-V600EBraf) are indicated. (e) RT-PCR analysis for tyrosinase (Tyr), silver (Si), melanocyte-
specific MITF (Mitf-M), Dct, Sox10, Pax3, Pou3f2, and Gapdh (loading control) in tumors (T), kidney (K), or liver (L) from three V600EBraf::K14-Kitl mice
(no. 453, no. 804, and no. 806). (f) Photomicrograph showing S100-positive nuclear and cytoplasmic staining of V600EBraf::K14-Kitl tumor. Bar¼ 50mm.
(g) Photomicrograph of the hematoxylin and eosin (H&E)-stained section showing intact epidermis, dermal localization of the tumor, and dermal nevus remnants
(black arrow). Bar¼ 200 mm. (h) Photomicrograph of H&E-stained section showing paucicellular spindle and dendritic cell (black arrowhead) composition of
early tumor in the dermis. Bar¼ 50mm. (i) Low-magnification photomicrograph of the H&E-stained section of an asymmetric, locally aggressive V600EBraf::K14-
Kitl tumor. Black arrow indicates the presence of the intact epidermis and a nevus remnant in the reticular dermis. Asterisk indicates the presence of deep local
invasion of the muscular layer. Bar¼ 0.5 mm. (j) Photomicrograph of the H&E-stained section showing tumor ulceration (white arrow), the absence of epidermal
involvement in adjacent epidermis, and increased cellularity in an advanced tumor. Bar¼ 300mm. (k) Photomicrograph of the H&E-stained section showing
deep local invasion of the muscular layer. Bar¼300 mm. (l) Photomicrographs showing localization of tumors in the dermis and the absence of epidermal
involvement. Upper panel: bar¼ 300 mm, lower panel: bar¼50 mm. (m) Photomicrograph of the H&E-stained section showing increased cellularity in the
more advanced lesions. Cells adopt a spindle-shaped morphology and a high number of mitoses are evident (white arrowheads). Bar¼ 50mm.
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mouse epidermis does not provide the
microenvironment necessary for V600EB-
raf-driven melanomagenesis.
There are several plausible expla-
nations as to why epidermal mela-
noma developed in the Tyr-Q61KNras::
p19Arf/::K14-Kitl, but not in the
V600EBraf::K14-Kitl or mGluR1::K14-Kitl
mice. UV light is critical for efficient
melanomagenesis in Tyr-Q61KNras::
p19Arf/ mice (Ferguson et al., 2010)
and has been shown to recruit melano-
cytes to the epidermis of neonatal
mice (Walker et al., 2009). Perhaps
the exogenous KITL traps these newly
recruited melanocytes and simply in-
creases the chance that epidermal
melanoma will develop, or perhaps it
provides a microenvironment that sup-
ports melanomagenesis in this popula-
tion in this location. Alternatively,
differences in the timing of oncogene
expression (prenatal in Tyr-Q61KNras::
p19Arf/ mice, induced in juveniles in
V600EBraf::K14-Kitl and mGluR1::
K14-Kitl mice), whether p19Arf is de-
leted or not, or the genetic background
of the mice (pure C57BL6 compared
with mixed FVB/C57BL6) could ac-
count for the differences. Clearly, these
are testable hypotheses and, although
the KITL did not translocate V600EBraf
melanoma to the epidermis, it in-
creased tumor penetrance and reduced
tumor latency and does therefore pro-
vide a considerably more robust and
versatile mouse model of melanoma.
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TO THE EDITOR
Two major phenotypes of genetic in-
stability characterize cancer cells.
Although the majority of cancers are
hallmarked by large chromosomal al-
terations and aneuploidy, some cancers
are diploid or near diploid, but show
insertion/deletion mutations at repeti-
tive sequences, termed as microsatel-
lites (de la Chapelle, 2003).
The pathogenetic mechanism asso-
ciated with microsatellite instability at
multiple microsatellite loci in cancer
(high-level microsatellite instability,
MSI-H) is deficient of the DNA mis-
match repair (MMR) system (de la
Chapelle, 2003). Functional MMR
assures correct replication of DNA
sequences and is essentially rele-
vant for the correction of mismatches
resulting from polymerase slippage at
Abbreviations: BCC, basal cell carcinoma; MMR, mismatch repair; MSI-H, high-level microsatellite
instability; NMSC, non-melanoma skin cancer; SCC, squamous cell carcinoma
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